menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Cytokinetics Starts Comet-HF Ph 3 Trial for Heart Failure Treatment

    GLOBENEWSWIRE

    U.S. FDA declines to approve Cytokinetics` heart drug

    REUTERS

    Cytokinetics` heart drug fails to secure FDA panel`s support

    REUTERS

    FDA staff reviewers flag safety concerns over Cytokinetics` heart drug

    REUTERS

    Cytokinetics Announces Availability of Documents for FDA Meeting on Omecamtiv Mecarbil

    GLOBENEWSWIRE

    Cytokinetics Announces Date for FDA Meeting to Review NDA for Omecamtiv Mecarbil

    GLOBENEWSWIRE

    Cytokinetics Provides Regulatory Update Related to NDA for Omecamtiv Mecarbil

    GLOBENEWSWIRE

    Cytokinetics` heart drug fails a phase 3 as it awaits FDA nod

    FIERCEBIOTECH

    Cytokinetics Announces FDA Acceptance of NDA for Omecamtiv Mecarbil

    GLOBENEWSWIRE

    Cytokinetics, Royalty partner on heart failure drug for $450M

    ENDPTS

    Cytokinetics and JI XING Announce Expansion of Collab to Include Licensing

    GLOBENEWSWIRE

    Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF

    GLOBENEWSWIRE

    Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF

    GLOBENEWSWIRE

    Cytokinetics Completed Enrollment in 2nd Ph3 Trial of Omecamtiv Mecarbil

    GLOBENEWSWIRE

    Amgen to transition devP& commercial rights for omecamtiv mecarbil

    PHARMABIZ

    Amgen kicks heart failure med back to Cytokinetics after `GALACTIC` flop

    FIERCEBIOTECH

    FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure

    PRESS RELEASE

    Oramed Reports +VE Results in the Final Cohort of Its Ph2b Oral Insulin Trial

    PR NEWSWIRE

    Cytokinetics Announces Design Of Galactic-Hf, A Ph3 Trial Of Omecamtiv Mecarbil

    PRESS RELEASE

    Analysis counters concerns about Amgen heart failure drug

    FIERCE BIOTECH

    Amgen Starts Phase III Enrollment for Heart Failure Drug

    NASDAQ

    Amgen, Servier start second phase 3 trial of heart failure hope

    PMLIVE

    MHRA issues drug safety warning for Neo-mercazole in pregnancy

    PHARMA TIMES

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.